Effect of hyperbaric oxygen on patients with traumatic brain injury.

Department of Neurosurgery, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan.
Acta neurochirurgica. Supplement (Impact Factor: 1.79). 01/2008; 101:145-9. DOI: 10.1007/978-3-211-78205-7_25
Source: PubMed

ABSTRACT Hyperbaric oxygen therapy (HBOT) is the medical therapeutic use of oxygen at a higher atmospheric pressure. The United States Food and Drug Administration have approved several clinical applications for HBOT, but HBOT in traumatic brain injury (TBI) patients has still remained in controversial. The purpose of our study is to evaluate the benefit of HBOT on the prognosis of subacute TBI patients. We prospectively enrolled 44 patients with TBI from November 1, 2004 to October 31, 2005. The study group randomly included 22 patients who received HBOT after the patients' condition stabilization, and the other 22 corresponding condition patients were assigned into the matched control group who were not treated with HBOT. The clinical conditions of the patients were evaluated with the Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) before and 3 to 6 months after HBOT. The GCS of the HBOT group was improved from 11.1 to 13.5 in average, and from 10.4 to 11.5 (p < 0.05) for control group. Among those patients with GOS = 4 before the HBOT, significant GOS improvement was observed in the HBOT group 6 months after HBOT. Based on this study, HBOT can provide some benefits for the subacute TBI patients with minimal adverse side effects.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic Brain Injury (TBI) affects a large proportion and extensive array of individuals in the population. While precise pathological mechanisms are lacking, the growing base of knowledge concerning TBI has put increased emphasis on its understanding and treatment. Most treatments of TBI are aimed at ameliorating secondary insults arising from the injury; these insults can be characterized with respect to time post-injury, including early, intermediate, and late pathological changes. Early pathological responses are due to energy depletion and cell death secondary to excitotoxicity, the intermediate phase is characterized by neuroinflammation and the late stage by increased susceptibility to seizures and epilepsy. Current treatments of TBI have been tailored to these distinct pathological stages with some overlap. Many prophylactic, pharmacologic, and surgical treatments are used post-TBI to halt the progression of these pathologic reactions. In the present review, we discuss the mechanisms of the pathological hallmarks of TBI and both current and novel treatments which target the respective pathways.
    International Journal of Molecular Sciences 01/2013; 15(1):309-341. DOI:10.3390/ijms15010309 · 2.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The neuroprotective properties for certain medical gases have been observed for decades, leading to extensive research that has been widely reported and continues to garner interest. Common, gases including oxygen, hydrogen, carbon dioxide and nitric oxide, volatile anesthetics such as, isoflurane, sevoflurane, halothane, enflurane and desflurane, non-volatile anesthetics xenon and, nitrous oxide, inert gases such as helium, argon and even gases classically considered to be toxic (e.g., hydrogen sulfide and carbon monoxide) have all been supported by evidence alluding to their use as, potential neuroprotective agents. A wide range of neural injury types such as ischemic/hemorrhagic, stroke, subarachnoid hemorrhage, traumatic brain injury, perinatal hypoxic-ischemic brain injuries, neurodegenerative disease as well as spinal cord ischemia, have been used as platforms for studying, the neuroprotective effects of these gases, yet until now, none of the gases has been widely introduced, into clinical use specifically for protection against neural injury. Insufficient clinical data together with, contradictory paradigms and results further hinders the clinical. However, pre-clinical models suggest, that, despite the various classes of gases and the broad range of injuries to which medical gases confer, protection, several underlying mechanisms for their neuroprotective properties are similar. In this, review, we summarize the literature concerning the neuroprotective effect of each gas and its, underlying mechanisms, extract common targets reported for the neuroprotective effects of different, gases, highlight the conflicting observations from clinical trials and further discuss the possible, hindrances impeding clinical applications in order to propose future research perspectives and, therapeutic exploitations.
    Progress in Neurobiology 01/2014; DOI:10.1016/j.pneurobio.2014.01.001 · 10.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many studies suggest that hyperbaric oxygen therapy (HBOT) can provide some clinically curative effects on blast-induced traumatic brain injury (bTBI). The specific mechanism by which this occurs still remains unknown, and no standardized time or course of hyperbaric oxygen treatment is currently used. In this study, bTBI was produced by paper detonators equivalent to 600 mg of TNT exploding at 6.5 cm vertical to the rabbit's head. HBO (100 % O2 at 2.0 absolute atmospheres) was used once, 12 h after injury. Magnetic resonance spectroscopy was performed to investigate the impact of HBOT on the metabolism of local injured nerves in brain tissue. We also examined blood-brain barrier (BBB) integrity, brain water content, apoptotic factors, and some inflammatory mediators. Our results demonstrate that hyperbaric oxygen could confer neuroprotection and improve prognosis after explosive injury by promoting the metabolism of local neurons, inhibiting brain edema, protecting BBB integrity, decreasing cell apoptosis, and inhibiting the inflammatory response. Furthermore, timely intervention within 1 week after injury might be more conducive to improving the prognosis of patients with bTBI.
    Neurochemical Research 03/2014; DOI:10.1007/s11064-014-1292-4 · 2.55 Impact Factor

Preview (2 Sources)

Available from